Literature DB >> 22185186

Why not real economics?

F Reed Johnson1.   

Abstract

Mesh:

Substances:

Year:  2012        PMID: 22185186     DOI: 10.2165/11593350-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  6 in total

1.  Are QALYs an appropriate measure for valuing morbidity in acute diseases?

Authors:  M V Bala; G A Zarkin
Journal:  Health Econ       Date:  2000-03       Impact factor: 3.046

2.  Conjoint Analysis Applications in Health - How are Studies being Designed and Reported?: An Update on Current Practice in the Published Literature between 2005 and 2008.

Authors:  Deborah Marshall; John F P Bridges; Brett Hauber; Ruthanne Cameron; Lauren Donnalley; Ken Fyie; F Reed Johnson
Journal:  Patient       Date:  2010-12-01       Impact factor: 3.883

3.  Things are Looking up Since We Started Listening to Patients: Trends in the Application of Conjoint Analysis in Health 1982-2007.

Authors:  John F P Bridges; Elizabeth T Kinter; Lillian Kidane; Rebekah R Heinzen; Colleen McCormick
Journal:  Patient       Date:  2008-12-01       Impact factor: 3.883

Review 4.  Utility measurement in healthcare: the things I never got to.

Authors:  George W Torrance
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Healthcare rationing by proxy: cost-effectiveness analysis and the misuse of the $50,000 threshold in the US.

Authors:  John F P Bridges; Eberechukwu Onukwugha; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  Is there a role for benefit-cost analysis in environmental, health, and safety regulation?

Authors:  K J Arrow; M L Cropper; G C Eads; R W Hahn; L B Lave; R G Noll; P R Portney; M Russell; R Schmalensee; V K Smith; R N Stavins
Journal:  Science       Date:  1996-04-12       Impact factor: 47.728

  6 in total
  1 in total

1.  Real economics needs to reflect real decisions: a response to Johnson.

Authors:  Mark Sculpher; Karl Claxton
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.